Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05374421 · ClinicalTrials.gov registry record · NA
Efficacy of the Erchonia Corporation THL™ for Providing Relief of Tinnitus Symptoms
A NA study, sponsored by Erchonia Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT05374421: Clinical Trial NA study, sponsored by Erchonia Corporation.
NCT05374421 is a NA study that was terminated before completion, run by Erchonia Corporation. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05374421, a NA study, was terminated before completion, sponsored by Erchonia Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to determine the effectiveness of the Erchonia® THL™, manufactured by Erchonia Corporation (the Company), for prescription home use in providing relief of tinnitus symptoms when used by individuals in their own homes.
Primary Outcome
The Tinnitus Functional Index (TFI) has been highly recommended to be used in both clinical and research settings for tinnitus measurement (Meikle et al., 2011). The self-report questionnaire, consists of 25 items with a response option on an 11-point Likert scale from 0-10. The calculation of overall TFI score is as follows: (1) Sum all valid answers. (2) Divide by the number of questions for which the sum of the valid answers was based to yield the respondent's mean item score. (3) Multiply by
Interventions
- DEVICE Placebo Laser
- DEVICE Erchonia® THL™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2022-12-09 |
| Phase | NA |
Why NCT05374421 stopped before completion
NCT05374421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Laser is the first listed.
NCT05374421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05374421 about?
NCT05374421 is a clinical study titled "Efficacy of the Erchonia Corporation THL™ for Providing Relief of Tinnitus Symptoms". The purpose of this clinical study is to determine the effectiveness of the Erchonia® THL™, manufactured by Erchonia Corporation (the Company), for prescription home use in providing relief of tinnitus symptoms when used by individuals in their own homes.
What is the current status of trial NCT05374421?
This trial is currently terminated. It is a NA study. The enrollment target is 23 participants. The study started on 2022-05-10. Estimated completion is 2022-12-09.
What interventions are being tested in trial NCT05374421?
The interventions under investigation include: Placebo Laser (DEVICE), Erchonia® THL™ (DEVICE).
Who is sponsoring clinical trial NCT05374421?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05374421's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI